Display options
Cite
Carvalho SB, Freire JM, Moleirinho MG, et al. Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles. Bioconjug Chem. 2016;27(10):2386-2399doi: 10.1021/acs.bioconjchem.6b00372.
Carvalho, S. B., Freire, J. M., Moleirinho, M. G., Monteiro, F., Gaspar, D., Castanho, M. A. R. B., Carrondo, M. J. T., Alves, P. M., Bernardes, G. J. L., & Peixoto, C. (2016). Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles. Bioconjugate chemistry, 27(10), 2386-2399. https://doi.org/10.1021/acs.bioconjchem.6b00372
Carvalho, Sofia B, et al. "Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles." Bioconjugate chemistry vol. 27,10 (2016): 2386-2399. doi: https://doi.org/10.1021/acs.bioconjchem.6b00372
Carvalho SB, Freire JM, Moleirinho MG, Monteiro F, Gaspar D, Castanho MARB, Carrondo MJT, Alves PM, Bernardes GJL, Peixoto C. Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles. Bioconjug Chem. 2016 Oct 19;27(10):2386-2399. doi: 10.1021/acs.bioconjchem.6b00372. Epub 2016 Oct 07. PMID: 27652605; PMCID: PMC5080633.
Copy Download .nbib Format: NLM
Share it on

Bioconjug Chem. 2016 Oct 19;27(10):2386-2399. doi: 10.1021/acs.bioconjchem.6b00372. Epub 2016 Oct 07.

Bioorthogonal Strategy for Bioprocessing of Specific-Site-Functionalized Enveloped Influenza-Virus-Like Particles.

Bioconjugate chemistry

Sofia B Carvalho, João M Freire, Mafalda G Moleirinho, Francisca Monteiro, Diana Gaspar, Miguel A R B Castanho, Manuel J T Carrondo, Paula M Alves, Gonçalo J L Bernardes, Cristina Peixoto

Affiliations

  1. Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa , Avenida da República, 2780-157 Oeiras, Portugal.
  2. iBET, Instituto de Biologia Experimental e Tecnológica , Apartado 12, 2780-901 Oeiras, Portugal.
  3. Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa , Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal.
  4. Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa , 2829-516 Monte da Caparica, Portugal.
  5. Department of Chemistry, University of Cambridge , Lensfield Road, CB2 1EW Cambridge, United Kingdom.

PMID: 27652605 PMCID: PMC5080633 DOI: 10.1021/acs.bioconjchem.6b00372

Abstract

Virus-like particles (VLPs) constitute a promising platform in vaccine development and targeted drug delivery. To date, most applications use simple nonenveloped VLPs as human papillomavirus or hepatitis B vaccines, even though the envelope is known to be critical to retain the native protein folding and biological function. Here, we present tagged enveloped VLPs (TagE-VLPs) as a valuable strategy for the downstream processing and monitoring of the in vivo production of specific-site-functionalized enveloped influenza VLPs. This two-step procedure allows bioorthogonal functionalization of azide-tagged nascent influenza type A hemagglutinin proteins in the envelope of VLPs through a strain-promoted [3 + 2] alkyne-azide cycloaddition reaction. Importantly, labeling does not influence VLP production and allows for construction of functionalized VLPs without deleterious effects on their biological function. Refined discrimination and separation between VLP and baculovirus, the major impurity of the process, is achieved when this technique is combined with flow cytometry analysis, as demonstrated by atomic force microscopy. TagE-VLPs is a versatile tool broadly applicable to the production, monitoring, and purification of functionalized enveloped VLPs for vaccine design trial runs, targeted drug delivery, and molecular imaging.

References

  1. Mol Ther Methods Clin Dev. 2016 Jan 27;3:15050 - PubMed
  2. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 Mar-Apr;3(2):174-96 - PubMed
  3. Biochemistry. 1992 Oct 13;31(40):9609-21 - PubMed
  4. Protein Eng Des Sel. 2011 Jan;24(1-2):53-63 - PubMed
  5. J Extracell Vesicles. 2014 Feb 04;3:null - PubMed
  6. J Virol. 2011 Aug;85(15):7546-54 - PubMed
  7. Nat Rev Microbiol. 2014 Nov;12(11):739-49 - PubMed
  8. J Am Chem Soc. 2004 Nov 24;126(46):15046-7 - PubMed
  9. Science. 1941 Jul 4;94(2427):22-3 - PubMed
  10. Bioconjug Chem. 2015 Aug 19;26(8):1590-6 - PubMed
  11. Expert Rev Vaccines. 2013 Feb;12(2):225-36 - PubMed
  12. Expert Rev Vaccines. 2015 Jul;14(7):913-5 - PubMed
  13. BMC Biotechnol. 2015 May 16;15:31 - PubMed
  14. J Biotechnol. 2007 Jan 10;127(3):452-61 - PubMed
  15. J Virol. 2012 Mar;86(6):2919-29 - PubMed
  16. Biotechnol Bioeng. 2014 Mar;111(3):425-40 - PubMed
  17. Bioconjug Chem. 2008 Apr;19(4):866-75 - PubMed
  18. Vaccine. 2014 Dec 12;32(52):7115-21 - PubMed
  19. Vaccine. 2001 Oct 12;20(1-2):92-7 - PubMed
  20. Cytotechnology. 2007 Sep;55(1):1-2 - PubMed
  21. Nat Protoc. 2012 Jun 14;7(7):1311-26 - PubMed
  22. Nat Protoc. 2014 Nov;9(11):2663-81 - PubMed
  23. Methods. 2006 Sep;40(1):60-5 - PubMed
  24. Angew Chem Int Ed Engl. 2009;48(50):9493-7 - PubMed
  25. Nat Methods. 2015 May;12(5):411-4 - PubMed
  26. Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9798-803 - PubMed
  27. Trends Biotechnol. 2013 Nov;31(11):654-63 - PubMed
  28. Curr Opin Biotechnol. 2007 Dec;18(6):537-45 - PubMed
  29. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):19-24 - PubMed
  30. Nat Biotechnol. 2005 May;23(5):567-75 - PubMed
  31. Gene Ther. 2009 Jun;16(6):766-75 - PubMed
  32. Biotechnol Bioeng. 2013 Jul;110(7):1964-72 - PubMed
  33. Front Microbiol. 2012 Jan 03;2:269 - PubMed
  34. Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):16998-7003 - PubMed
  35. J Virol. 2007 Oct;81(20):10890-6 - PubMed
  36. Front Microbiol. 2012 Nov 09;3:391 - PubMed

Publication Types

Grant support